Liu, Yanwei <br/><br/>
Mefloquine effectively targets gastric cancer cells through phosphatase-dependent inhibition of PI3K/Akt/mTOR signaling pathway.  [electronic resource] 

 -  Biochemical and biophysical research communications  Feb 2016 
 - 350-355 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1090-2104 
<br/><br/><label>Standard No.: </label>10.1016/j.bbrc.2016.01.046  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antineoplastic Agents--administration & dosage<br/>Apoptosis--drug effects<br/>Cell Line, Tumor<br/>Cell Proliferation--drug effects<br/>Dose-Response Relationship, Drug<br/>Humans<br/>Mefloquine--administration & dosage<br/>Mice<br/>Mice, SCID<br/>Molecular Targeted Therapy--methods<br/>Oncogene Protein v-akt--metabolism<br/>Phosphatidylinositol 3-Kinases--metabolism<br/>Phosphoric Monoester Hydrolases--metabolism<br/>Signal Transduction--drug effects<br/>Stomach Neoplasms--drug therapy<br/>TOR Serine-Threonine Kinases--metabolism<br/>Treatment Outcome